NEW YORK (GenomeWeb) – Canaccord Genuity has upgraded its rating for Genomic Health to Buy from Hold, the investment banking company said today.

After surveying and interviewing urologists, Canaccord analyst Mark Massaro wrote in his note, the bank found that Genomic Health has the best brand awareness for its cancer tests. "To our surprise, more docs responded they are aware of GHDX's test over MYGN's test, despite MYGN's first mover advantage, which we think is a testament to GHDX's solid early marketing and commercial initiatives," he added.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

The Economist writes that an increasing number of scientific journals don't do peer review.

In Science this week: genetic overlap among many psychiatric disorders, and more.